South Korea Botulinum Toxin Type A Market Summary

The South Korea botulinum toxin type A market size was estimated at USD 194.1 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2030. This upward trend is primarily driven by the rising demand for aesthetic procedures, technological advancements, and expanding applications for existing products. According to a news article published in March 2024, approximately one in five women in South Korea had undergone plastic surgery, highlighting a robust cultural acceptance and growing popularity of cosmetic treatments across the country. This societal trend continues to fuel consistent demand for botulinum toxin injections.

The market is witnessing robust growth supported by continuous innovations in technology and treatment techniques. A May 2022 MDPI article highlighted a wide array of commercial products offered by both domestic and international companies. The introduction of products such as Liztox by Humedix and ReNTox by PharmaResearch Bio reflects the industry’s commitment to innovation and product diversification. The availability of cost-effective, locally developed botulinum toxin formulations has played a key role in expanding patient access and increasing market penetration. This competitive pricing and product variety have not only driven local market growth but also contributed to influencing trends in the global botulinum toxin landscape.

Key Market Trends & Insights

• The upper face segment held the largest share of over 51.85% in 2023, driven by the rising popularity of treatments aimed at minimizing facial wrinkles in areas such as the forehead, glabella, and crow’s feet. A May 2022 NCBI article revealed that glabellar wrinkles were the most commonly treated area in the upper face by dermatologists in Korea, accounting for 40.9% of procedures, followed by forehead wrinkles at 36.1% and crow’s feet at 22.9%. These preferences highlight the demand for subtle yet effective aesthetic interventions that rejuvenate the face while preserving natural expressions.
• The female demographic accounted for the largest share of 82.02% in 2023, underlining the significant influence of women in driving demand for botulinum toxin procedures. The high demand stems from factors such as early signs of aging, skin laxity, and dullness, which are often influenced by hormonal changes, including declining estrogen levels. Women in South Korea are particularly proactive about skincare and aesthetic enhancement, contributing to sustained growth in the female consumer segment.
• In terms of age, individuals between 31 and 59 years held the largest share of over 44.35% in 2023. This age group is particularly conscious of aging signs like fine lines and wrinkles, making them a major target audience for aesthetic interventions involving botulinum toxin type A. Their interest in non-invasive solutions to maintain a youthful appearance continues to stimulate product demand in clinical settings and contributes to steady market growth.
• The specialty clinics and aesthetic centers segment accounted for the largest market share of over 42.99% in 2023. These facilities offer comprehensive cosmetic treatment options tailored to individual needs, often under the guidance of experienced professionals. Their popularity is increasing due to the availability of specialized expertise, convenience, and a high standard of personalized care. As more consumers seek efficient and reliable aesthetic solutions, these dedicated centers are expected to remain dominant within the healthcare delivery landscape for botulinum toxin services.

Order a free sample PDF of the South Korea Botulinum Toxin Type A Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 194.1 Million
• 2030 Projected Market Size: USD 386.9 million
• CAGR (2024 - 2030): 10.4%

Key Companies & Market Share Insights

Some of the key players operating in the industry include Hugel, Medytox and Daewoong. Company’s key strategies include understanding the strengths and weaknesses of major market participants, anticipating future market trends, opportunities, and challenges, and making proactive decisions based on insights into emerging technologies and changing consumer preferences. For instance, Huons Global and Pharma Research BIO are some of the emerging players in the South Korea botulinum toxin type A industry. These industry players are continuously focused on niche segments, leveraging specialized technologies to differentiate themselves.

Key Players

• Hugel
• Medytox
• Daewoong
• Galderma
• Ipsen
• Huons Global
• Pharma Research BIO
• AbbVie

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The South Korea botulinum toxin type A market is witnessing steady growth driven by a beauty-conscious population, technological advancements, and rising demand for non-invasive cosmetic procedures. With significant contributions from domestic brands and a highly competitive pricing environment, the market offers a diverse range of solutions for facial rejuvenation. Upper face treatments and services targeting women aged 31–59 dominate the landscape, while specialty clinics continue to lead in service delivery. As aesthetic preferences evolve and innovation continues, the market is well-positioned for sustained expansion, making South Korea a key hub for botulinum toxin development and aesthetic procedure adoption in the Asia-Pacific region.